Brain Data Articles & Analysis
10 news found
EMOTIV, the bioinformatics pioneer advancing understanding of the human brain using electroencephalography (EEG), today added two renowned scientists to its executive leadership team, naming Dr. Gary William Flake as Chief Technology Officer (CTO) and Dr. Scott Rickard as Chief AI Scientist. The new hires underscore EMOTIV’s strategic objectives to meet the quickening pace of advancements ...
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD. Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that ...
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31–Aug. 4, 2022, in San Diego. Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard ...
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in the U.S. using an endovascular BCI approach, which does not require invasive open-brain surgery. The procedure was performed at Mount Sinai West in ...
Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation's leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon's machine learning neuroanalytics platform. EEG is standard of care in the clinical diagnosis and management of many neurologic diseases ...
Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the ...
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have established a research collaboration with Principal Investigator Dr Takashi Nakajima, MD, PhD at Niigata Hospital and Dr Kazuo Shigematsu at Minami Kyoto National Hospital. In Japan, clinical MRI scanners are available for ...
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety ...
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment ...
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...